Call your doctor before leaving home if you think you’ve been exposed to COVID-19 or have symptoms

Due to the presence of COVID-19 in our community, visitor restrictions are in place for all Duke clinics and hospitals. For your safety and the safety of others, we recommend patients do not bring a visitor to Duke clinics, if at all possible. If a visitor must accompany a patient, only one individual over 12 years of age is allowed. Patients and visitors will be screened for symptoms upon arrival. Individuals with flu-like symptoms are not allowed. View the complete list of Visitor Restrictions.

Effective immediately, Duke Health is prioritizing and rescheduling some non-emergent or non-critical surgeries, procedures, and appointments. Check our COVID-19 (Coronavirus) page for updates.

Performance of Epi proColon in Repeated Testing (PERT) - Clinical Trial

What is the Purpose of this Study?

This study is testing an FDA-approved blood test that screens for colorectal cancer (CRC). It is being tested as an alternative for patients who are reluctant or who refuse to undergo screening colonoscopy or stool testing to screen for CRC. This study is confirming the accuracy of this blood test when used with repeated yearly testing.
What is the Condition Being Studied?
Colon cancer screening

Who Can Participate in the Study?

Patients aged 51-75 with average-risk of colon cancer (no family history, no personal history of polyps or CRC) who have declined CRC screening.

Patients must be willing and able to have a colonoscopy if the Epi proColon blood test is positive.

Age Group

What is Involved?

If you choose to join this study:

You will have a blood test called the Epi proColon test drawn at your first visit.

If this test is negative, you will come back in 1 year to have the same blood test repeated.

- If, at either of the 2 visits, your test is positive, you will need to have a colonoscopy.

The study team will help you set up this colonoscopy.

Study Details

Full Title
Performance of Epi proColon in Repeated Testing in the Intended Use Population (PERT)
Principal Investigator
Protocol Number
IRB: PRO00085544
NCT: NCT03218423
Contact the Duke Recruitment Innovation Center